Theratechnologies Announces Completion of the Pre-License Inspection of the Ibalizumab Manufacturing Facility

Aug 03, 2017
PDF Version
Supporting Materials:

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it has been notified by its partner, TaiMed Biologics, Inc. (TaiMed), that the U.S. Food and Drug Administration (FDA) has completed the PreLicense Inspection (PLI) of the WuXi Biologics Inc. (WuXi) facility where ibalizumab will be manufactured.